Quick Heal Technologies Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Flat revenue, heavy investment: Revenue stayed flat around ₹300 crores while R&D spend jumped ~39% YoY and sales & marketing rose 9%, compressing EBITDA margin to 1.72%.
• Enterprise is the growth engine: Enterprise business grew ~50% YoY to ~₹22 crores in Q1, while consumer retail remained flattish at ₹41 crores, constrained by a stagnant market and low consumer awareness.
• New products are in market-building mode: Zero Trust, EDR and data privacy products have launched and acquired their first paid customer, but management says product-market fit takes 4–6 quarters, so material revenue is not expected until H1 FY24.
• ₹150 crore buyback proposed: Board approved a tender-route buyback at ₹300 per share, with promoters participating proportionately to stay below the 75% SEBI shareholding cap; expected to conclude in 3.5–4 months.
• What to watch next quarter: Whether the increased sales & marketing spend begins converting into revenue growth, any further enterprise customer wins for the new Zero Trust and data privacy products, and the pace of the buyback execution.

Enterprise Business: The Growth Story

• Strong Q1 momentum: Enterprise revenue reached ~₹22 crores, up ~50% YoY, driven primarily by the endpoint security (EPS) product; the business has now reached an ₹82–85 crore annual run-rate.
• SMB stronghold, moving upmarket: The company holds 15–20% market share in the SMB segment and is gradually shifting toward larger customers, with recent wins including BITS Pilani, Fino Payment Bank and Emami Cement; no particular vertical focus, targeting across industries.
• Private sector dominates: Predominant enterprise sales come from the private sector, with similar CAGR growth across government and private customers, though management declined to disclose the exact split, calling it "confidential and proprietary information."
• Competitive set: Current enterprise competitors include Trend Micro, SOPHOS and McAfee; for the new Zero Trust and data privacy products, the company expects to compete with ZScalar, One Trust, SOPHOS and Symantec, though most competitors' products in these categories are still at an early stage.

Kailash Katkar: "Had our investments were not made in endpoint security 5-7 years ago when we were predominantly taking a lead on retail business. Probably this entity currently would have been at minus 82 or 85 crore revenue."

Consumer Retail: The Cash Cow Under Pressure

• Stagnant market, flat revenue: Consumer segment revenue was flattish at ₹41 crores, constrained by a domestic retail market growing at barely 1% and a global consumer industry growing at only 4%.
• Low awareness caps the opportunity: Only 20–25% of laptops in India are covered by antivirus, despite a 50% increase in PC and laptop sales post-COVID; management sees this as a large latent opportunity but acknowledges consumer awareness is the binding constraint.
• Market leadership maintained: Quick Heal remains the undisputed market leader in India with 30%+ share, growing at lower single digits versus a 1% market growth rate over the last 2–3 years.
• Long-term demand-generation bets: Increased sales & marketing spend is directed at digital demand generation, SEO and marketing, investments management frames as long-term and not expected to yield immediate results; these same investments helped grow retail in prior years against a flat market.

Sanjay Katkar: "We are not like only focus on enterprise. The focus is on both. Only thing is a consumer is on a different trajectory so the retail products are facing what is the trend in the market. But at the same time we are maintaining our market share."

New Products: Zero Trust, EDR & Data Privacy

• Product suite taking shape: The company has launched HawkkHunt (EDR) last year, Zero Trust User Access (ZTUA) early this year, and HawkkScan (data privacy) early this year; a centralized dashboard, HawkkEye, now integrates EPS, EDR and HawkkScan, with ZTUA integration expected soon.
• First paid ZTUA customer secured: The Zero Trust user access product captured its first paid customer in Q1 FY23, marking an early milestone; some zero trust and data privacy products are already in the market as beta versions.
• Revenue timeline is H1 FY24: Management is explicit that these products are establishing product-market fit, a process that typically takes 4 to 6 quarters, so material revenues are expected to flow in from H1 of FY24.
• Additive, not cannibalistic: The new products are additional solutions over and above existing endpoint products, not replacements; the same enterprise customer needs both, so the new suite expands wallet share rather than displacing the legacy portfolio.
• Addressable market expanding: The focused market potential in new product categories is projected to reach ~₹190 crores by FY27, up from the current ~₹70 crores.
• Regulatory tailwind possible: India's data protection regulation, similar to GDPR, has been under discussion for over a year and is hoped to come into effect by next September; once enacted, enterprises will need to spend on data protection products, directly benefiting HawkkScan.

Sanjay Katkar: "we are establishing product market fit for all these products, which typically takes around 4 to 6 quarters, and you can expect revenues to flow in from H1 of FY24."

Margins & Investment Cycle

• EBITDA compressed to near-breakeven: EBITDA margin stood at 1.72% in Q1, driven by a ~39% YoY increase in R&D expenses and a 9% YoY rise in sales & marketing spend at the consolidated level; revenues are seasonal while costs are not, amplifying the Q1 margin hit.
• Investment, not maintenance: Management frames the expense growth as directed toward developing next-generation versions of existing BAU products and building entirely new products in zero trust and data privacy, not as maintenance-mode spending; the endpoint security business, now at ₹82–85 crores, is cited as proof that past investment cycles pay off.
• Industry-wide cost escalation: The entire IT industry is facing cost escalation, and Quick Heal is no different; heavy investment in R&D and sales & marketing is expected to continue, making near-term EBITDA difficult to forecast.
• No R&D tax benefit available: The deduction under Section 35-2AB was abolished 3–4 years ago, so the increased R&D spend flows straight to the bottom line with no tax shield.
• Capex is immaterial: R&D is the major investment; capital expenditure is insignificant in the large scheme of things.

Capital Allocation & Buyback

• ₹150 crore buyback approved: The board approved a tender-route buyback at ₹300 per share for 50 lakh shares, representing 8.6% of paid-up capital; the transaction is expected to conclude in 3.5 to 4 months.
• Promoter participation is structural: Promoters must participate proportionately to keep their shareholding below the 75% SEBI limit; without participation, their stake would breach the cap.
• Post-buyback cash position: Close to ₹200 crore will remain available after the buyback and dividend for the right organic and inorganic growth opportunities.
• Israeli entity investment: The company has made a sizable stake investment in an Israeli entity working on technology different from Quick Heal's own; the entity is moving in the right direction on product development, though the investment amount itself is small.

Navin Sharma: "See, you might be aware that promoters share is 70% to 73% in the organization if our buyback happens without participation from promoter, then certainly their shareholding would increase beyond 75% which is not permissible under SEBI law."

Strategy & Leadership

• New senior hires onboarded: Ashish Pradhan joined as Chief Technology Officer and Sudhanshu Tripathi as VP and Head of Marketing, both bringing significant domain experience.
• Top-three global consultancy engaged: The company has begun an engagement with one of the big three multinational consulting firms to develop a long-term strategic growth plan.
• 50-50 revenue mix target: Management's stated goal is to reach a 50-50 revenue split between retail and enterprise within the coming two years.
• Product suite roadmap: The four current products (EPS, EDR, ZTUA, data privacy, plus the HawkkEye dashboard) will cover basic customer needs; as the majority of customers grow, the company will look at introducing a further suite of products, with research already ongoing on that front.
• Geographic concentration: More than 95% of revenue comes from India; the Russia-Ukraine war has not impacted the company.

Kailash Katkar: "And as I said in earlier investor calls, also my focus is in coming two years they will reach to 50-50 ratio about the revenue ratio of 50-50 percent from a retail as well as the enterprise part of it."

Guidance & Commitments

Key Metrics